Hypoglycemia Patents (Class 514/884)
-
Patent number: 9000222Abstract: The present invention includes compounds, pharmaceuticals and cosmetics having at least one (substituted phenyl)-propenal moiety. The compounds and compositions of the present invention are useful in the treatment or prevention of medical conditions including androgen associated conditions, androgen associated inflammation, a wound (the compounds assist with wound healing), acne, rheumatoid arthritis, psoriasis, rosacea, and alopecia; Kennedy's disease (spinal and bulbar muscular atrophy, or SBMA), polyglutamine-mediated motor neuron degeneration; cancers such as prostate cancer, bladder cancer, breast cancer, ovarian cancer, hepatocellular (liver) cancer, and pancreatic cancer; and other medical conditions described herein. Treatment of such medical conditions includes administering to an individual suffering from a medical condition describe herein, a therapeutically effective amount of any of the disclosed compounds, their derivatives, or pharmaceutical compositions thereof.Type: GrantFiled: June 18, 2013Date of Patent: April 7, 2015Assignee: Androscience CorporationInventors: Charles Shih, Qian Shi, Hui-Kang Wang
-
Patent number: 8846646Abstract: The invention relates to an unexpected discovery that propylene glycol is highly effective at killing or inhibiting Propionibacterium acnes in a mammalian skin disorder, as well as to the use of propylene glycol and salicylic acid in a skin-disorder treatment. This invention also relates to compositions containing propylene glycol alone or in combination with salicylic acid for use in killing or inhibiting Propionibacterium acnes.Type: GrantFiled: October 3, 2008Date of Patent: September 30, 2014Assignee: Winlind Skincare, LLCInventor: Win L Chiou
-
Patent number: 8513225Abstract: Disclosed herein is a composition containing a high concentration of PG is unexpectedly capable of quickly killing other bacteria, fungi, and/or virus in vitro that is indicative of its potential high efficacy in treating various skin infection. Embodiments disclosed herein relate to a composition and method for effective topical treatment of inflammatory skin lesions in mammals, comprising of a high concentration of propylene glycol alone, or in combination with an astringent. The PG at high concentrations can be regarded as an extremely effective, safe, topical, universal, microbicide.Type: GrantFiled: April 5, 2011Date of Patent: August 20, 2013Assignee: Winlind Skincare, LLCInventor: Win L Chiou
-
Patent number: 7964201Abstract: A concentrate including, by weight (a) 10% to 60%, preferably 25% to 35%, of a saturated fatty acid selected from stearic or palmitic acid, or mixtures thereof, in an adduct of an amidopropyldimethyl-2-hydroxyethyl ammonium halide, with substantially no free acid present, and (b) 40% to 90%, preferably 65% to 75%, of a low molecular weight alcohol or saturated fatty alcohol or alcohols, for use in personal care products, including hair care and skin care compositions.Type: GrantFiled: May 12, 2005Date of Patent: June 21, 2011Assignee: ISP Investments Inc.Inventors: Steven H. Bertz, Ilya Makarovsky
-
Patent number: 7098193Abstract: The present disclosure provides compositions comprising an extracted portion of psyllium seed in combination with one or more of a binder, suspending agent, or edible acid. In particular, the present invention is directed to compositions comprising: (a) a polysaccharide component comprising xylose and arabinose, wherein the ratio of xylose to arabinose is at least about 3:1, by weight; and (b) a dispersing component selected from the group consisting of binders, suspending agents, edible acids, and mixtures thereof. In a preferred embodiment, the compositions further comprise an aqueous liquid, for example, water or juice (e.g., fruit or vegetable juice). As such, the present invention further relates to methods of preparing a product comprising admixing the present compositions with an aqueous liquid. The present compositions are useful for the treatment of a variety of benefits, including providing treatment for gastrointestinal conditions or providing other gastrointestinal benefits.Type: GrantFiled: August 4, 2003Date of Patent: August 29, 2006Assignee: The Procter & Gamble CompanyInventors: Graham John Myatt, Paul Alfred Cimiluca
-
Patent number: 7026303Abstract: The present disclosure provides compositions comprising a plurality of agglomerates comprising a polysaccharide component comprising xylose and arabinose, wherein the ratio of xylose to arabinose is at least about 3:1, by weight; wherein the compositions further comprise: (i) optionally, a first surrounding layer which surrounds the agglomerate, wherein the first surrounding layer is a hydrophobic layer; and (ii) optionally, a second surrounding layer which surrounds the agglomerate, wherein the second surrounding layer is a hydrophilic layer; wherein the compositions comprise at least one of the first surrounding layer and the second surrounding layer, and wherein when the agglomerate comprises the first surrounding layer and the second surrounding layer then the first surrounding layer is a preceding layer relative to the second surrounding layer.Type: GrantFiled: August 4, 2003Date of Patent: April 11, 2006Assignee: The Procter & Gamble CompanyInventors: Paul Alfred Cimiluca, Graham John Myatt
-
Patent number: 6982254Abstract: The present disclosure provides compositions comprising an extracted portion of psyllium seed in combination with one or more of a binder or edible acid. In particular, the present invention is directed to compositions comprising a polysaccharide component comprising xylose and arabinose, wherein the ratio of the xylose to the arabinose is at least about 3:1, by weight, and wherein the polysaccharide particles have a mean particle size distribution of from about 0.001 microns to about 150 microns. In a further embodiment, the compositions comprise a plurality of agglomerates comprising the polysaccharide component and a dispersing component selected from binders, suspending agents, edible acids, and mixtures thereof. In yet a further embodiment, the compositions comprise agglomerates comprising a polysaccharide component, wherein the agglomerates have a mean particle size distribution of from about 100 to about 500 microns.Type: GrantFiled: August 4, 2003Date of Patent: January 3, 2006Assignee: The Procter & Gamble CompanyInventors: Paul Alfred Cimiluca, Graham John Myatt, Hasani Gillispie
-
Patent number: 6890568Abstract: A composition for managing blood glucose levels is herein described. The composition comprises decocted tea and vanadate and does not cause the same side effects as vanadate and water mixtures known in the prior art. Specifically, the vanadate suspended in decocted tea does not cause diarrhea and in some cases stabilizes blood glucose at normal levels for several weeks after only a few treatments.Type: GrantFiled: September 17, 2002Date of Patent: May 10, 2005Inventors: Grant Pierce, Clayton Heyliger
-
Patent number: 6797283Abstract: The present invention is directed to a multilayered dosage form which is adapted for retention in the stomach and useful for the prolonged delivery of an active agent to a fluid environment of use. The active agent dosage form is a multilayer core, often bilayer, formed of polymer matrices that swell upon contact with the fluids of the stomach. At least one layer of the multilayered dosage form includes an active agent. A portion of the polymer matrices are surrounded by a band of insoluble material that prevents the covered portion of the polymer matrices from swelling and provides a segment of the dosage form that is of sufficient rigidity to withstand the contractions of the stomach and delay expulsion of the dosage form from the stomach until substantially all of the active agent has been dispensed.Type: GrantFiled: December 22, 1999Date of Patent: September 28, 2004Assignee: Alza CorporationInventors: David E. Edgren, Francisco Jao, Patrick S. -L. Wong
-
Patent number: 6770635Abstract: Adverse inflammatory reactions can be treated by administrating to an organism a composition having diglucosylamine as the active ingredient. The preferred compound is di-Beta-D-glucopyranosylamine. A simple method for making diglucosylamine in high purity is obtained by reacting glucose, a nitrogen containing base, and either methanol or ethanol to form the diglucosylamine and then recovering the diglucosylamine preferably with the use of charcoal. The preferred diglucosylamine, di-Beta-D-glucopyranosylamine, has extraordinary anti-inflammatory activity. It can be formulated with a pharmaceutically acceptable carrier to make pharmaceutical compositions which are effective in treating inflammations. This pharmaceutical composition can also be used to treat adverse inflammatory reactions that are the result of the disruptions of a dynamic network of cellular mechanisms in organisms.Type: GrantFiled: December 4, 1997Date of Patent: August 3, 2004Assignee: Pharos PharmaceuticalsInventor: Clairmont G. Drube
-
Patent number: 6663874Abstract: A composition for use by animals, including humans, to alleviate pain and/or inflammation around a painful joint, joint replacement surgery site, muscle, tendon, and/or ligament. A method to ameliorate pain and/or inflammation in or around a joint, muscle, tendon, and/or ligament, by topically applying Applicant's composition.Type: GrantFiled: January 19, 2001Date of Patent: December 16, 2003Inventor: Victor Stevens
-
Patent number: 6635655Abstract: The use of diaryl acid derivatives of formula (I) or pharmaceutically acceptable salts, N-oxides, hydrates or solvates thereof, wherein the variables shown are defined in the disclosure, and their pharmaceutical compositions as PPAR ligand receptor binders. The PPAR ligand receptor binders of this invention are useful as agonists or antagonists of the PPAR receptor.Type: GrantFiled: September 14, 2000Date of Patent: October 21, 2003Assignee: Aventis Pharma Deutschland GmbHInventors: Zaid Jayyosi, Gerard M. McGeehan, Michael F. Kelley, Richard F. Labaudiniere, Litao Zhang, Robert D. Groneberg, Daniel G. McGarry, Thomas J. Caulfield, Anne Minnich, Mark Bobko
-
Patent number: 6573291Abstract: The invention relates to a method of antagonizing GLP-1 activity in a mammalian patient, comprising administering to said patient an effective amount of a compound of the general formula I: wherein R1 and R2 independently of each other are C1-4alkyl, R3 is halogen, hydroxy, C1-4-alkoxy or trifluoromethoxy, R4 is hydrogen, hydroxy or C1-4-alkoxy, or a pharmacologically acceptable salt thereof. The invention also relates to a pharmaceutical composition comprising a compound of formula I.Type: GrantFiled: December 3, 2001Date of Patent: June 3, 2003Assignee: Biovitrum ABInventors: Alvar Gronberg, Jerry R. Colca
-
Patent number: 6410511Abstract: The present invention is concerned with a pharmaceutical formulation in a container, for example, a vial, prefilled cartridge, prefilled syringe or disposable pen, comprising approximately 0.01 to about 0.5% (w/v) amylin agonist, preferably pramlintide, in an aqueous system along with approximately 0.02 to about 0.5% (w/v) of an acetate, phosphate, citrate, or glutamate buffer to a pH of the final composition of approximately 3.0 to about 6.0 as well as approximately 1.0 to 10% (w/v) of a carbohydrate or polyhydric alcohol tonicifier; and, optionally, approximately 0.005 to 1.0% (w/v) of a preservative selected from the group consisting of m-cresol, benzyl alcohol, parabens and phenol. These formulations maintain stability upon storage under refrigerated or room temperature conditions. Such formulations can be further combined with insulin in the same syringe for administration to a patient.Type: GrantFiled: January 9, 1998Date of Patent: June 25, 2002Assignee: Amylin Pharmaceuticals, Inc.Inventors: James L'Italien, Shankar Musunuri, Kale Ruby
-
Patent number: 6376512Abstract: A method for mediating the activity of PPAR-&ggr; receptor comprising contacting said PPAR-&ggr; receptor with a compound of formula I defined herein. Also disclosed is the treatment of a patient suffering from a physiological disorder capable of being modulated by a compound of formula I having PPAR-&ggr; ligand binding activity, comprising administering to the patient a pharmaceutically acceptable amount of the compound, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: January 27, 2000Date of Patent: April 23, 2002Assignee: Aventis Pharma Deutschland GmbHInventors: Zaid Jayyosi, Gerard M. McGeehan, Michael F. Kelley
-
Patent number: 6048514Abstract: Novel methods for use in identifying or assaying compounds which can simulate the ability of amylin to cause hyperlactemia and hyperglycemia in in vivo biological models, or for use in evaluating the potency of compounds known or suspected to simulate these actions of amylin, which involve introducing test samples into in vivo test systems and determining the presence or amount of a rise in lactate, or determining the presence or amount of a rise in lactate and a rise in glucose, following test sample administration.Type: GrantFiled: April 14, 1995Date of Patent: April 11, 2000Assignee: Amylin Pharmaceuticals, Inc.Inventors: Andrew A. Young, Garth J. S. Cooper, Timothy J. Rink
-
Patent number: 5925647Abstract: Novel cryptolepine analogs useful as hypoglycemic agents and methods for their use as hypoglycemic agents, for example, in the treatment of diabetes, and a method for their synthesis are described. As hypoglycemic agents, the novel cryptolepine analogs are useful for the treatment of insulin-dependent diabetes mellitus (IDDM or Type I) and non-insulin dependent diabetes mellitus (NIDDM or Type II).Type: GrantFiled: October 20, 1997Date of Patent: July 20, 1999Assignee: Shaman Pharmaceuticals, Inc.Inventor: Donald E. Bierer
-
Patent number: 5888993Abstract: There are provided vanadium compositions for use in the treatment of hypertension, obesity and diabetes, in particular improved oral compositions comprising oxovanadium (IV) chelates of monoprotic, bidentate oxygen, oxygen and oxygen, nitrogen coordinating ligands especially kojic acid, maltol and ethyl maltol.Type: GrantFiled: November 3, 1997Date of Patent: March 30, 1999Assignee: The University of British ColumbiaInventors: John Hugh McNeil, Chris Orvig
-
Patent number: 5866563Abstract: There are provided vanadium compositions for use in the treatment of hypertension, obesity and diabetes, in particular improved oral compositions comprising oxovanadium (IV) chelates of monoprotic, bidentate oxygen, oxygen and oxygen, nitrogen coordinating ligands especially kojic acid, maltol and ethyl maltol.Type: GrantFiled: June 7, 1995Date of Patent: February 2, 1999Assignee: The University of British ColumbiaInventors: John Hugh McNeil, Chris Orvig
-
Patent number: 5846544Abstract: The present invention concerns a method and composition for reducing blood sugar levels in diabetic human subjects. Practice of the invention requires ingestion of bilberry fruit and valerian root in timed relation to meals. Neither bilberry fruit nor valerian root alone achieve the lowering and regulation of blood sugar levels achieved by the combination. Practice of the invention requires ingestion of bilberry fruit with valerian root.Type: GrantFiled: July 11, 1997Date of Patent: December 8, 1998Inventor: Holly Christine Al-Dahir
-
Patent number: 5837255Abstract: The use of extracts from Harungana or Vismia spp. or anthracenone compounds harunganin and vismin contained therein or isolated therefrom as hypoglycemic agents, as well as methods for obtaining the hypoglycemic agents are described. According to a preferred embodiment, the extracts are derived from H. madagascariensis. As hypoglycemic agents, the extracts or anthracenone compounds harunganin and vismin are useful for treating insulin-dependent (type I) and non-insulin-dependent (type II) diabetes.Type: GrantFiled: December 10, 1996Date of Patent: November 17, 1998Assignee: Shaman Pharmaceuticals, Inc.Inventors: Wayne DeWald Inman, Jian Luo
-
Patent number: 5773004Abstract: Disclosed is the composition for treating or curing diabetes mellitus containing an ingredient or component suitable for treatment of diabetes mellitus from an extract obtained by immersing a plant belonging to genus Tithonia and/or Ludwigia in a pharmacologically acceptable solvent for a predetermined period of time, said plant belonging to genus Tithonia being Tithonia diversifolia (Hemsl.) A. Gray, Tithonia rotundifolia (Mill) Blake, Tithonia fruticosa Canby & Rose, Tithonia scaberrima Benth. or Tithonia longeradiata (Bertol) Brake; and said plant belonging to genus Ludwigia being Ludwigia octovalvis Raven or Ludwigia prostrata Roxb. or Ludwigia epilobioides Maxim. The composition administered in the form of tea or drink or other formulation to a diabetic patient by first applying a composition containing an extract from the plant belonging to genus Tithonia and thereafter applying a composition containing an extract from the plant belonging to genus Ludwigia.Type: GrantFiled: October 30, 1995Date of Patent: June 30, 1998Inventor: Masakiyo Takahashi
-
Patent number: 5760047Abstract: The present invention is directed to an improvement in a method of weight and/or body-fat reduction comprising a (preferably moderate) reduction in the caloric intake of a subject in need of such treatment in combination with administration to said subject of a prolactin inhibitor. Additionally, the present invention is directed to an improvement in a method for altering and/or resetting prolactin profiles (and thereby controlling one or more metabolic disorders such as obesity, excessive body fat, hyperlipidemia, hyperlipoproteinemia, hyperglycemia, hypercholesterolemia, hyperinsulinemia, insulin resistance, glucose intolerance, and Type II diabetes) comprising administration to a subject in need of such treatment of a prolactin inhibitor at a predetermined time or times during a 24-hour period in combination with a (preferably moderate) reduction of the caloric intake of said subject.Type: GrantFiled: May 10, 1995Date of Patent: June 2, 1998Assignees: The Board of Supervisors of Louisiana State University and Agriculture and Mechanical College, Ergo Research CorporationInventors: Anthony H. Cincotta, Albert H. Meier
-
Patent number: 5635529Abstract: Novel O-substituted or O-unsubstituted 6-sulfonamido-1,3-dioxepane-5-ols having hypoglycemic activity are obtained from 6-amino-1,3-dioxepane-5-ol, tetrahydro-6H-[1,3]-dioxepino[5,6-d]oxazole, 5,6-epoxy-1,3-dioxepane or N-sulfonyl-tetrahydro-1H,4H-[1,3]-dioxepino[5,6-b]azirine as starting materials.Type: GrantFiled: February 17, 1995Date of Patent: June 3, 1997Assignee: PLIVA farmaceutska, kemijska, prehrambena i kozmeticka industrija, dionicko drustvo ZagrebInventors: Miljenko Dumic, Darko Filic, Mladen Vinkovic, Blanka Jamnicky
-
Patent number: 5631245Abstract: Adverse inflammatory reactions can be treated by administrating to an organism a composition having diglucosylamine as the active ingredient. The preferred compound is di-Beta-D-glucopyranosylamine. A simple method for making diglucosylamine in high purity is obtained by reacting glucose, a nitrogen containing base, and either methanol or ethanol to form the diglucosylamine and then recovering the diglucosylamine preferably with the use of charcoal. The preferred diglucosylamine, di-Beta-D-glucopyranosylamine, has extraordinary anti-inflammatory activity. It can be formulated with a pharmaceutically acceptable carrier to make pharmaceutical compositions which are effective in treating inflammations. This pharmaceutical composition can also be used to treat adverse inflammatory reactions that are the result of the disruptions of a dynamic network of cellular mechanisms in organisms.Type: GrantFiled: June 6, 1995Date of Patent: May 20, 1997Assignee: Biodynamics Pharmaceuticals, Inc.Inventor: Clairmont G. Drube
-
Patent number: 5629319Abstract: The use of extracts from Cryptolepis sp. or quindoline alkaloids such quindoline and cryptolepine contained therein as hypoglycemic agents, as well as methods for obtaining the hypoglycemic agents are described. According to a preferred embodiment, the extracts are derived from Cryptolepis sanguinolenta. As hypoglycemic agents, the extracts or quindoline alkaloids such as quindoline or cryptolepine are useful for treating insulin-dependent (type I) and non-insulin-dependent (type II) diabetes.Type: GrantFiled: June 6, 1995Date of Patent: May 13, 1997Assignee: Shaman Pharmaceuticals, Inc.Inventors: Jian Luo, Diana M. Fort, Donald E. Bierer, Reimar C. Bruening
-
Patent number: 5594005Abstract: Quinoline-3-carboxamide compounds of formula (I) are effective in preventing, treating or ameliorating Type I diabetes. ##STR1## wherein ----- represents two conjugated double bonds between the atoms comprised by the dashed line, X.sub.1 and X.sub.2 are independently selected from an oxygen atom or NH.sup.9, H.sup.1-9 independently represent a hydrogen atom or a substituent, wherein H.sup.7 and H.sup.8 are attached to different atoms selected from X.sub.1, X.sub.2 and the ring nitrogen atom of the quinoline ring. In particular, X.sub.1 and X.sub.2 being bound by a single bond to the ring when H.sup.7 or H.sup.8 is bonded thereto and by a double bond when H.sup.7 or H.sup.8 is not bonded thereto.Type: GrantFiled: December 23, 1994Date of Patent: January 14, 1997Assignee: Pharmacia ABInventors: Shimon Slavin, Lola Weiss, David Gross
-
Patent number: 5576306Abstract: Water-soluble, high-viscosity grade cellulose ether compositions are useful for the reduction of serum lipid levels, particularly total serum cholesterol, serum triglycerides, and low-density lipoprotein (LDL) levels and/or attenuate the postprandial rise of blood glucose levels in animals. The pharmaceutical uses of compositions for reducing cholesterol levels additionally include the treatment of diabetes and/or hypercholesterolemia, with avoidance of many of the undesirable side effects associated with other forms of treatment. The composition may be in the form of a prehydrated ingestible composition, such as a gelatin, or a comestible, such as a cookie. In addition, the compositions of the present invention are palatable to the patient, thereby enhancing patient compliance with the regimen.Type: GrantFiled: December 9, 1994Date of Patent: November 19, 1996Assignees: Dow Chemical Company, Board of Regents Acting for and on Behalf of the University of MichiganInventors: Jennifer B. Dressman, Christos Reppas, Stephen W. Tobey, Cynthia W. Sowle
-
Patent number: 5569655Abstract: Substitutued heterocyclylisoquinolinium salts, pharmaceutical compositions containing them and methods for the treatment or prevention of neurodegenerative disorders or neurotoxic injuries utilizing them.Type: GrantFiled: July 29, 1994Date of Patent: October 29, 1996Assignee: Sterling Winthrop Inc.Inventors: John A. Dority, Jr., William G. Earley, Virendra Kumar, John P. Mallamo, Matthew S. Miller, Chakrapani Subramanyam
-
Patent number: 5527790Abstract: There are provided vanadium compositions for use in the treatment of hypertension, obesity and diabetes, in particular improved oral compositions comprising oxovanadium (IV) chelates of monoprotic, bidentate oxygen, oxygen and oxygen, nitrogen coordinating ligands especially kojic acid and maltol.Type: GrantFiled: March 18, 1994Date of Patent: June 18, 1996Assignee: The University of British ColumbiaInventors: John H. McNeill, Chris Orvig
-
Patent number: 5512296Abstract: A method for inhibiting neuronal damage due to hypoglycemia comprising administering to a human in need thereof an effective amount of a compound having the formula ##STR1## wherein R.sup.1 and R.sup.3 are independently hydrogen, --CH.sub.3, ##STR2## wherein Ar is optionally substituted phenyl; R.sup.2 is selected from the group consisting of pyrrolidine, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.Type: GrantFiled: August 22, 1994Date of Patent: April 30, 1996Assignee: Eli Lilly and CompanyInventor: George J. Cullinan
-
Patent number: 5356879Abstract: This invention discloses the usefulness of D-tagatose as a treatment for hyperglycemia, diabetes mellitus, and the inhibition of formation of advanced glycosylation end-products associated with the aging process.This invention discloses edible formulations and pharmaceutical compositions containing D-tagatose and the effect of consumption of such formulations on blood level of glucose. D-Tagatose was found to be an anti-hyperglycemic agent. In addition, consumption of D-tagatose in sweetened formulations to inhibit formation of advanced glycosylation end-products in mammals is disclosed. The combination of the anti-hyperglycemic effect and the inhibition of formation of glycosylated proteins and nucleic acids make D-tagatose an ideal agent for alleviating the complications resulting from hyperglycemia, including acceleration of the aging process.Type: GrantFiled: February 14, 1992Date of Patent: October 18, 1994Assignee: Biospherics, IncorporatedInventors: Lee R. Zehner, Gilbert V. Levin, James P. Saunders, James R. Beadle
-
Patent number: 5300496Abstract: A pharmaceutical composition useful for lowering blood sugar and suppressing appetite in mammals. The composition comprises compounds of a formula selected from VOL.sub.2 or VO(OR)L.sub.2 in which L is a bidentate monoprotic ligand and R is an organic group. The composition includes a pharmaceutically acceptable carrier. The invention also provides a method of lowering blood sugar and suppressing appetite in a mammal that comprises administering to the mammal a compound of the above formula.Type: GrantFiled: September 30, 1991Date of Patent: April 5, 1994Assignee: The University of British ColumbiaInventors: John H. McNeill, Hamid R. Hoveyda, Chris Orvig
-
Patent number: 5281584Abstract: The present invention is directed to a baked food composition comprising food ingredients and a water-soluble cellulose ether which is useful for reducing the low-density lipoprotein serum cholesterol level of an animal. Use of a specific particle-size distribution of the water-soluble cellulose ether results in compositions which are more palatable than known compositions.Type: GrantFiled: February 28, 1992Date of Patent: January 25, 1994Assignee: The Dow Chemical CompanyInventor: Stephen W. Tobey
-
Patent number: 5209920Abstract: Inbred Lewis (LEW/N) female rats develop an arthritis in response to Group A streptococcal cell wall peptidoglycanpolysaccharide (SCW) which mimics human rheumatoid arthritis. Histocompatible Fischer (F344/N) rats, on the other hand, do not develop arthritis in response to the same SCW stimulus. To evaluate this difference in inflammatory reactivity between the two strains, the function of the hypothalamic-pituitary-adrenal axis and its ability to modulate the development of the inflammatory response was studied. It has been found that, in contrast to F344/N rats, LEW/N rats had markedly impaired plasma ACTH and corticosterone responses to SCW, recombinant human Interleukin-1 alpha (IL-1 alpha), the serotonin agonist, quipazine, and synthetic rat corticotropin-releasing hormone (CRH). In addition, LEW/N rats compared to F344/N rats had smaller adrenal glands and larger thymuses. Treatment of LEW/N rats with replacement doses of dexamethasone decreased the severity of their SCW-induced arthritis.Type: GrantFiled: September 25, 1989Date of Patent: May 11, 1993Assignee: The United States of America as represented by the United States Department of Health and Human ServicesInventors: Esther M. Sternberg, Ronald L. Wilder, Philip W. Gold, George P. Chrousos
-
Patent number: 5190916Abstract: A treating agent such as a wound therapeutic agent, inflammation therapeutic agent, hair growth agent and hair tonic, and a cosmetic, comprising as an effective component ovomacroglobulin are disclosed. They can act on the skin, a scalp or hairs to exhibit excellent wound curing promotion effect, hair growth promotion effect, and skin or hair protective effect.Type: GrantFiled: February 8, 1988Date of Patent: March 2, 1993Assignees: Japan Immuno Research Laboratories Co., Ltd., Otsuka Pharmaceutical Co., Ltd.Inventor: Masakazu Adachi
-
Patent number: 5183823Abstract: There is disclosed a novel thiazolidinedione derivative of the general formula (I): ##STR1## wherein R.sup.1 and R.sup.2 are the same or different and are a hydrogen atom or a lower alkyl group, or a salt thereof. The thiazolidinedione derivative has hypoglycemic activity and hypolipidemic activity.Type: GrantFiled: March 31, 1992Date of Patent: February 2, 1993Assignee: Takeda Chemical Industries, Ltd.Inventors: Takashi Sohda, Hitoshi Ikeda
-
Patent number: 5179079Abstract: The systemic absorption after intranasal administration of certain drugs, in particular pharmacologically active polypeptides is enhanced in the presence of a phospholipid, such as a phosphatidylcholine (a lecithin), preferably admixed with a vegetable oil.Type: GrantFiled: November 27, 1991Date of Patent: January 12, 1993Assignee: Novo Nordisk A/SInventors: Philip E. Hansen, Anders R. Sorensen
-
Patent number: 5141927Abstract: Alginates capable of binding sodium and having ion exchanging capacity are used in conjunction with vitamin D for the treatment of hypertension. Such alginates may be acid extracted from seaweeds such as Asophylum nodosum. The acid-extracted alginate may be converted, for example, to potassium alginate prior to administration or mixing with vitamin D to form pharmaceutical compositions.Type: GrantFiled: July 26, 1990Date of Patent: August 25, 1992Inventor: Marcin Krotkiewski
-
Patent number: 5110595Abstract: Implant preparations capable of sustained action when inserted are comprised of powder of a natural lipoidal substance in thorough admixture with bioactive macromolecule, followed by compression under pressure into a disc or rod that can be broken and used in small pieces as well.Type: GrantFiled: June 19, 1987Date of Patent: May 5, 1992Inventor: Paul Y. Wang
-
Patent number: 5091524Abstract: Salbostatin, a compound of the formula I ##STR1## acts as a glycosidase inhibitor and is suitable for use in pharmacy and in plant protection.Type: GrantFiled: October 26, 1989Date of Patent: February 25, 1992Assignee: Hoechst AktiengesellschaftInventors: Laszlo Vertesy, Hans-Wolfram Fehlhaber, Arno Schulz
-
Patent number: 5008248Abstract: A veterinary composition comprising 75-85% of an actively absorbed monosaccharide, from 3.5 to less than 5% of an actively absorbed naturally occurring amino acid, 5-10% of one or more citrate salts. The composition is useful in the treatment of diarrhoea in domestic animals such as calves.Type: GrantFiled: January 30, 1990Date of Patent: April 16, 1991Assignee: Beecham Group p.l.c.Inventors: Robert J. Bywater, Robert J. Dupe
-
Patent number: 4985439Abstract: A glucose tolerance factor which reduces blood sugar in mammals and is derived from yeast. The glucose tolerance factor can be isolated from autolyzed brewer's yeast extract by sequential fractionation on Sephadex G-75, Biogel P-6, Biogel P-2, to give a purified glucose tolerance factor. By further purification, a substantially purified glucose tolerance factor is obtained which is a quinoline derivative with a molecular ion at 174 by mass spectrometry.Type: GrantFiled: February 14, 1990Date of Patent: January 15, 1991Assignee: Anheuser-Busch Companies, Inc.Inventors: David Hwang, Arye Lev-Ran, Ken Barseghian, deceased
-
Patent number: 4968790Abstract: Phosphates are disclosed which stimulate the enzyme fructose-1,6-bisphosphatase and inhibit the enzyme 6-phosphofructo-1-kinase, thereby lowering glucose levels in mammals. These phosphates may thus be used to treat hyperglycemia and/or diabetes. Processes for the synthesis of the phosphates are also disclosed.Type: GrantFiled: October 28, 1988Date of Patent: November 6, 1990Assignee: American Cyanamid CompanyInventors: Vern G. DeVries, Thomas H. Claus, Middleton B. Floyd, Jr., Semiramis Ayral-Kaloustian
-
Patent number: 4918099Abstract: A novel drug comprises as active ingredient an extract extractable from plant material of plants belonging to the genus Caesalpinia, one or several components of this extract and/or one or several substances present in this extract or derived therefrom but prepared synthetically.These substances are in particular benz(b)indeno(2.1-d)pyran derivatives, including brazilin, brazilein, hematoxylin and/or hematein. The drug is especially suited for treatment of a patient suffering from micro-circulatory disorders, diabetes mellitus, increased blood sugar values, increasing blood platelet aggregation, increased blood viscosity, decreased eryhtrocyte deformability, disorders of the lysosomal enzyme activity and/or suffering from disorders of the prostaglandin metabolism, especially increasing thromboxane A.sub.2 activity.Type: GrantFiled: March 26, 1986Date of Patent: April 17, 1990Inventor: Chang-Kiu Moon
-
Patent number: 4859709Abstract: A pharmaceutical composition comprising a freely flowable powder, the powder comprising a porous, high absorption silica or silicate having absorbed therein at least 10% by volume of a liquid, pharmaceutically active composition, based on the weight of powder plus liquid, provided that when the liquid pharmaceutically active composition is a corticoid solution the silica or silicate has a mean particle size of at least 10 .mu.m in diameter.Type: GrantFiled: October 26, 1987Date of Patent: August 22, 1989Assignee: Beecham Group plcInventor: David A. Rawlins
-
Patent number: 4849211Abstract: A composition comprising squalene and saturated normal aliphatic hydrocarbons which is very effective in the treatment of acne, minor skin irritations and minor skin wounds, burns, inflammation and soreness when applied topically to the skin. Basically, the product comprises from about 5 to 40 volume percent squalene and from about 5 to 25 volume percent n-decane, n-dodecane or mixtures thereof with the balance being normal aliphatic hydrocarbons with chain lengths in the C10 to C35 range or a water-polysorbate emulsion. If desired, certain other ingredients such as zinc oxide or a filler may be added to the mixture. The product may be applied as a spray, cream or gel.Type: GrantFiled: March 16, 1988Date of Patent: July 18, 1989Inventor: Gerhard N. Schrauzer
-
Patent number: 4788306Abstract: There are disclosed compounds of the formula ##STR1## wherein R.sup.1 and R.sup.2 are each, independently, hydrogen, hydroxy, lower alkyl, lower alkoxy, haloloweralkyl, haloloweralkyl sulfonyl, halo or nitro;R.sup.3 is hydrogen, lower alkyl, or aryl of 7-12 carbon atoms; ##STR2## A is --CH.sub.2 --, --O-- or --S--; m is 1-8;n is 0-7, with the proviso that m+n.ltoreq.8;or a pharmacologically acceptable salt thereof, and their use as fatty acid oxidation inhibitors possessing a significantly reduced potential for impairment of normal cardiac function, and having particular utility in the treatment of glucose and fatty acid metabolism disorders, such as diabetes.Type: GrantFiled: August 21, 1987Date of Patent: November 29, 1988Assignee: American Home Products CorporationInventors: Guy A. Schiehser, Donald P. Strike
-
Patent number: 4764623Abstract: Compounds of the formula: ##STR1## where R is hydrogen or A--(CF.sub.2).sub.m --CH.sub.2 --; A is --F or --H; n is an integer from 1 to 10, inclusive; m is an integer from 0 to 9, inclusive; p is an integer from 0 to 4, inclusive; and Y is hydrogen, halo, trifluoromethyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, or hydroxy; or a pharmaceutically acceptable salt thereof. The compounds are useful as anti-hyperglycemic and anti-hyperinsulinemic agents.Type: GrantFiled: June 15, 1987Date of Patent: August 16, 1988Assignee: American Home Products CorporationInventor: Kenneth L. Kees
-
Patent number: 4734435Abstract: Disclosed herein are N-[[6-methoxy-5-(trifluoromethyl)-1-naphthalenyl]-thioxomethyl]-N-methylgl ycine S-oxide (tolrestat S-oxide) and the amide thereof and methods of their preparation. The S-oxides are new aldose reductase inhibitors useful for the treatment of prevention of diabetic complications.Type: GrantFiled: November 25, 1986Date of Patent: March 29, 1988Assignee: American Home Products Corp.Inventors: Eckhardt S. Ferdinandi, Michael S. Malamas, Kazimir Sestanj, Surendra N. Sehgal